Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lenvima Shows Non-Inferiority vs Nexavar in HBV Carriers Too: PIII Sub-Analysis
Eisai said on September 19 that its cancer drug Lenvima (lenvatinib) achieved non-inferiority to Nexavar (sorafenib) in the primary endpoint of overall survival (OS) in a subpopulation of hepatocellular carcinoma (HCC) patients infected with hepatitis B virus (HBV) in a…
To read the full story
Related Article
- Lenvima Stalls QOL Lowering in HCC Patients: Eisai
September 12, 2017
- Lenvatinib Filed for HCC in US and EU after Japan Submission
July 26, 2017
- Eisai Seeks HCC Indication for Lenvima in Japan
June 26, 2017
- Details Revealed for Lenvima’s Non-Inferiority Study vs Nexavar in 1st Line HCC
June 6, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in OS as Liver Cancer 1st Line Treatment
January 27, 2017
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…